NIAID Herpes Vaccine Research Study Seeks Volunteers
A new NIAID clinical research study investigates the safety of a herpes simplex virus (HSV) vaccine in people aged 18 to 40 years with and without HSV infection. Volunteers in the Washington, DC, metropolitan area who are in good general health are invited to participate in the study, which involves 12 study visits at the NIH Clinical Center in Bethesda, Maryland.
Did you know?
- In the United States about one out of six people aged 14 to 49 years have genital HSV‐2 infection
- Most people with genital herpes infection do not know they have it
- Sexual contact with genital herpes sores increases the risk of HIV transmission if either partner is HIV‐infected
Volunteer for a Clinical Research StudyEstablished in 1942, the NIAID Laboratory of Infectious Diseases (LID) has a long history of discovering new agents of viral diseases and developing innovative vaccines and treatments. The following are examples of Food and Drug Administration-approved medical advances in which LID scientists played a crucial role:
- FluMist, a nasal spray influenza vaccine licensed by MedImmune
- Synagis, a preventative treatment for respiratory syncytial virus licensed by MedImmune
- Havrix, a hepatitis A vaccine licensed by GlaxoSmithKline